A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

This is a Phase 1b/2 study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 in pediatric patients with relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B ALL) and r/r B cell Non-Hodgkin lymphoma (B NHL).

Trial Details

NCT ID
NCT06173518
Phase
PHASE1
Sponsor
Autolus Limited
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • AUTO1
Locations (sample)
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362
  • San Antonio, Texas, United States|29.42412,-98.49363
  • Salt Lake City, Utah, United States|40.76078,-111.89105
  • Barcelona, Spain|41.38879,2.15899
  • Madrid, Spain|40.4165,-3.70256

Key Eligibility Criteria

  • \< 18 years old at screening
  • ≥ 6 kg body weight at screening
  • Pediatric patients with r/r B ALL
  • r/r CD19-positive aggressive mature B including the B NHL subtypes: i) diffuse large B cell lymphoma, ii) Burkitt's lymphoma, iii) primary mediasti…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →